Skip to main content

Search
Profile

Douglas S Hawkins, MD

Douglas S Hawkins, MD

Douglas S Hawkins, MD

Hematology-Oncology

On staff since February 1996

Title:

Associate Division Chief, Hematology/Oncology

Academic Title:

Associate Professor, Pediatrics

Research Center:

Center for Clinical and Translational Research

Offices & Contact Information

Location
Address
Contact
Seattle Children's

Primary office location

B-6553 - Hematology-Oncology

4800 Sand Point Way NE

Seattle, WA 98105

Primary Phone:

(206) 987-2106

Professional History

Board Certified:

Pediatric Hematology-Oncology

Medical/Professional School:

Harvard Medical School, Boston

Residency:

University of Washington, Seattle, Pediatrics

Clinical Interests:

Sarcomas, New therapy

Research Focus Area:

Cancer

Description of Research:

My clinical research is particularly focused in the treatment of pediatric sarcomas. I am the Children's Oncology Group (COG) chair of the Soft Tissue Sarcoma Committee, which designs and conducts all national studies in pediatric soft tissue sarcomas, including rhabdomyosarcoma. I am the COG chair of two clinical trials, one for Ewing sarcoma and another for rhabdomyosarcoma, and the vice chair of three other COG clinical trials. I am working collaboratively on a pharmacogenomic study investigating cyclophospharmide metabolism and toxicity, both locally and as part of two COG studies, and on the use of FDG PET to assess response and guide treatment in pediatric sarcomas.

Key Publications:

Barker LM, Pendergrass TW, Sanders JE, and Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors, Journal of Clinical Oncology 2005; 23:4354-4362.

Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU, and Eary JF. [18F]-fluorodeoxy-D-glucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors, Journal of Clinical Oncology 2005; 23:8828-8834.

Hawkins DS, Bradfield S, Whitlock J, Krailo M, Franklin J, Blaney SM, Adamson PC, and Reaman G. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group Study. Pediatric Blood and Cancer 2006; 47:790-794.

Rodeberg DA, Stoner, JA, Hayes-Jordan A, Kao S, Wolden S, Qualman, S, Meyers W, and Hawkins DS. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma (RMS): a report from the Children's Oncology Group (COG), in press, Journal of Clinical Oncology.

Hawkins DS, Conrad EU, Butrynski JE, Schuetze SM, and Eary JF. [F-18]-fluorodeoxy-D-glucose positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults, in press, Cancer.

Honors & Awards:

Seattle Magazine Top Doc 2004-05, 2008

Seattle Metropolitan Magazine Top Doctor, 2006-09

Find a Doctor or Researcher

Find a Doctor or Researcher

Name:

Latest News

N.F.L. Picks New Chairmen for Panel on Concussions
3.17.10 — New York Times

Dr. Richard Ellenbogen named new co-chair of NFL head, neck and spine medical committee.

FDA warning changes the way children with asthma are treated
3.13.10 — King 5 TV

Dr. Greg Redding comments on the FDA’s updated recommendation on long acting beta-agonists for asthma management in ... cont.

Children's Hospital Plan Clears City Committee
3.12.10 — KUOW

Plans to expand Seattle Children's Hospital cleared a key committee at a recent Seattle City Council meeting.